Faron Pharmaceuticals Oy (LON:FARN) Insider Jurriaan Dekkers Sells 4,000 Shares

Key Points

  • Insider Jurriaan Dekkers sold 4,000 Faron shares on January 12 at an average price of GBX 182, for a total of £7,280.
  • Faron's stock has a market cap of about £206 million, a negative PE of -6.67 and an unusually high debt-to-equity ratio of 922.55, with a 12‑month range of GBX 146–270.
  • Faron is a clinical‑stage biopharma developing immune‑modulating treatments, notably Clevegen (bexmarilimab), which aims to switch immune suppression to activation in oncology and infectious disease.

Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) insider Jurriaan Dekkers sold 4,000 shares of the firm's stock in a transaction dated Monday, January 12th. The shares were sold at an average price of GBX 182, for a total value of £7,280.

Faron Pharmaceuticals Oy Stock Performance

Faron Pharmaceuticals Oy stock opened at GBX 180 on Wednesday. The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55. The stock has a market cap of £205.96 million, a PE ratio of -6.67 and a beta of 0.36. Faron Pharmaceuticals Oy has a 12-month low of GBX 146 and a 12-month high of GBX 270. The business's 50-day moving average price is GBX 183.65 and its two-hundred day moving average price is GBX 192.50.

About Faron Pharmaceuticals Oy

(Get Free Report)

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.

Further Reading

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Faron Pharmaceuticals Oy?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Faron Pharmaceuticals Oy and related companies.
From Our Partners
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles